Literature DB >> 18398023

Recruitment in the prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial: the first phase of recruitment at Henry Ford Health System.

Lois E Lamerato1, Pamela M Marcus, Gordon Jacobsen, Christine Cole Johnson.   

Abstract

OBJECTIVE: Recruitment of healthy subjects to long-term randomized controlled trials (RCTs) of cancer prevention or early detection has proven to be a difficult task. To quantify recruitment yield as well as characteristics of successfully recruited participants, we examined recruitment outcomes at 1 of the 10 centers participating in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial, a National Cancer Institute-funded RCT of cancer screening modalities.
MATERIALS AND METHODS: During the early recruitment phase of PLCO (1993-1997), data on recruitment outcome were collected at the Henry Ford Health System (HFHS) in Detroit, Michigan. In this phase, HFHS identified potential participants using patient databases. Records were used to assess recruitment success by age, sex, race, household income (using area-based U.S. Census data), and preexisting morbidity. Logistic regression was used to assess whether enrollment success differed significantly according to these factors.
RESULTS: Of 74,139 persons ages 55 to 74 invited by HFHS to participate, 8,250 (11%) ;enrolled. In multivariate analyses, the odds of enrolling were modestly but significantly higher for women, Caucasians, persons in their 60's, and persons living in census blocks with higher median household income. Persons with two or more preexisting morbidities had significantly lower odds of enrolling compared to those with one or no preexisting morbidities.
CONCLUSIONS: These data suggest that only a small fraction of persons invited to enroll in long-term RCTs of cancer screening modalities actually do so. In this urban, Midwestern setting, certain characteristics including age, race, and income influenced recruitment success, albeit modestly.

Entities:  

Mesh:

Year:  2008        PMID: 18398023     DOI: 10.1158/1055-9965.EPI-06-0528

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  10 in total

1.  The epidemiology of CA-125 in women without evidence of ovarian cancer in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial.

Authors:  Christine C Johnson; Bruce Kessel; Thomas L Riley; Lawrence R Ragard; Craig R Williams; Jian-Lun Xu; Saundra S Buys
Journal:  Gynecol Oncol       Date:  2008-06-30       Impact factor: 5.482

2.  Nonparticipation in a population-based trial to increase colorectal cancer screening.

Authors:  Beverly B Green; Andy Bogart; Jessica Chubak; Sally W Vernon; Leo S Morales; Richard T Meenan; Sharon S Laing; Sharon Fuller; Cynthia Ko; Ching-Yun Wang
Journal:  Am J Prev Med       Date:  2012-04       Impact factor: 5.043

Review 3.  Prostate cancer: Why the prostate arm of the PLCO trial failed and what it has taught us.

Authors:  Matthew R Cooperberg
Journal:  Nat Rev Urol       Date:  2016-07-12       Impact factor: 14.432

4.  Prostate Cancer Screening and the Goldilocks Principle: How Much Is Just Right?

Authors:  Izak Faiena; Stuart Holden; Mathew R Cooperberg; Stuart Holden; Howard R Soule; Jonathan W Simons; Todd M Morgan; David F Penson; Alicia K Morgans; Maha Hussain
Journal:  J Clin Oncol       Date:  2018-02-05       Impact factor: 44.544

Review 5.  Chronic obstructive pulmonary disease (COPD) and lung cancer screening.

Authors:  Robert P Young; Raewyn J Hopkins
Journal:  Transl Lung Cancer Res       Date:  2018-06

6.  Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study.

Authors:  Anita V Mitra; Elizabeth K Bancroft; Yolanda Barbachano; Elizabeth C Page; C S Foster; C Jameson; G Mitchell; G J Lindeman; A Stapleton; G Suthers; D G Evans; D Cruger; I Blanco; C Mercer; J Kirk; L Maehle; S Hodgson; L Walker; L Izatt; F Douglas; K Tucker; H Dorkins; V Clowes; A Male; A Donaldson; C Brewer; R Doherty; B Bulman; P J Osther; M Salinas; D Eccles; K Axcrona; I Jobson; B Newcombe; C Cybulski; W S Rubinstein; S Buys; S Townshend; E Friedman; S Domchek; T Ramon Y Cajal; A Spigelman; S H Teo; N Nicolai; N Aaronson; A Ardern-Jones; C Bangma; D Dearnaley; J Eyfjord; A Falconer; H Grönberg; F Hamdy; O Johannsson; V Khoo; Z Kote-Jarai; H Lilja; J Lubinski; J Melia; C Moynihan; S Peock; G Rennert; F Schröder; P Sibley; M Suri; P Wilson; Y J Bignon; S Strom; M Tischkowitz; A Liljegren; D Ilencikova; A Abele; K Kyriacou; C van Asperen; L Kiemeney; D F Easton; Rosalind A Eeles
Journal:  BJU Int       Date:  2010-09-14       Impact factor: 5.588

7.  Non-steroidal anti-inflammatory drug use and colorectal polyps in the Prostate, Lung, Colorectal, And Ovarian Cancer Screening Trial.

Authors:  Christine Cole Johnson; Richard B Hayes; Robert E Schoen; Marc J Gunter; Wen-Yi Huang
Journal:  Am J Gastroenterol       Date:  2010-08-31       Impact factor: 10.864

8.  Process evaluation of recruitment for a cancer screening trial in primary care.

Authors:  Aimee S James; Christine M Daley; Kimberly Engelman; K Allen Greiner; Edward Ellerbeck
Journal:  Health Promot Pract       Date:  2011-04-06

9.  A population-based cohort study of chest x-ray screening in smokers: lung cancer detection findings and follow-up.

Authors:  Lorenzo Dominioni; Nicola Rotolo; William Mantovani; Albino Poli; Salvatore Pisani; Valentina Conti; Massimo Paolucci; Fausto Sessa; Antonio Paddeu; Vincenzo D'Ambrosio; Andrea Imperatori
Journal:  BMC Cancer       Date:  2012-01-17       Impact factor: 4.430

10.  Feasibility of self-collection of fecal specimens by randomly sampled women for health-related studies of the gut microbiome.

Authors:  Heather Spencer Feigelson; Kimberly Bischoff; Mary-Anne E Ardini; Jacques Ravel; Mitchell H Gail; Roberto Flores; James J Goedert
Journal:  BMC Res Notes       Date:  2014-04-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.